FDA Inspection 1258760 — Smithers Pharmaceutical Development Services
The FDA completed an inspection of Smithers Pharmaceutical Development Services on Dec 13, 2024 in Gaithersburg, MD. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Dec 13, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Gaithersburg, MD (United States)
Additional Details
Bioanalytical BA/BE